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JOURNAL OF HEPATOLOGYHepatocyte iron accumulation: A new string to ribavirin’s
antiviral bow?count a potential role for iron in hepatocyte HCV eradication,
which may be transiently facilitated by ribavirin therapy. At the
very least, this potential mechanism of ribavirin action merits
further investigation.
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Building on previous work, the recent article by Fillebeen and
Pantopoulos elegantly demonstrates a role for iron as an inhibitor
of hepatitis C virus (HCV) replication [1]. Using HCV-infected
Huh7.5.1 hepatoma cells, the authors show a dose-dependent
reduction in the expression of HCV viral proteins and RNA upon
exogenous administration of iron. Moreover, the anti-viral effect
of iron was attributed to the direct inhibition of the HCV RNA
polymerase NS5B by iron [2].
However, the ﬁndings outlined in this article appear contrary
to the prevailing perception of the role of iron in HCV infection.
Disordered iron homeostasis is a frequent ﬁnding in HCV
patients, and may be associated with adverse clinical outcomes
[3]. An increased propensity to hepatic decompensation, an
increased incidence of hepatocellular carcinoma, and a reduced
response to treatment have all been reported in association with
excess serum or hepatic iron [4–6]. The authors acknowledge
these issues, and conclude by doubting whether iron-mediated
inhibition of HCV replication would represent a realistic thera-
peutic target. These sentiments were echoed in the accompany-
ing editorial [7].
The nucleoside analogue ribavirin forms a key component of
the current standard of care for HCV treatment, in combination
with pegylated interferon alpha. Despite its importance in aug-
menting treatment response and preventing relapse, its antiviral
mechanism of action remains elusive [8]. Curiously, signiﬁcant
hepatic iron accumulation has been reported in HCV patients
receiving ribavirin monotherapy for greater than 6 months
[9,10]. These ﬁndings were attributed to the well-documented,
dose-dependent haemolysis caused by ribavirin. However, excess
iron accumulated predominantly in hepatocytes, rather than in
phagocytic Kupffer cells, as might be expected following intravas-
cular haemolysis [10]. Although hepatic iron accumulation dur-
ing treatment was not associated with changes in liver
transaminases, it is unclear whether treatment response was
altered [10].
Iron accumulation in chronic HCV infection appears harmful.
Given the ﬁndings by Fillebeen et al., it would be difﬁcult to dis-Journal of Hepatology 2011 vol. 55 j 233–238 237
[9] Di Bisceglie AM, Bacon BR, Kleiner DE, Hoofnagle JH. Increase in hepatic iron
stores following prolonged therapy with ribavirin in patients with chronic
hepatitis C. J Hepatol 1994;21:1109–1112.
[10] Fiel MI, Schiano TD, Guido M, Thung SN, Lindsay KL, Davis GL, et al. Increased
hepatic iron deposition resulting from treatment of chronic hepatitis C with
ribavirin. Am J Clin Pathol 2000;113:35–39.
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Reply to: Hepatocyte iron accumulation: A new string to
ribavirin’s antiviral bow?
This is a reply to the letter to the Editor by Ryan and Crowe:
We thank Drs. J.D. Ryan and J. Crowe for their comments to our
recent article [1]. In their letter, they discuss earlier reports
showing that prolonged treatment of HCV-infected patients with
ribavirin associates with hepatic iron deposition, mainly in hepa-
tocytes [2,3]. This is largely attributed to extravascular hemolysis,
a known side effect of ribavirin ([2] and references therein) even
though one would expect a predominant distribution of excess
iron within Kupffer cells. The authors further hypothesise that
accumulation of iron within hepatocytes may potentiate the anti-
viral efﬁcacy of this therapeutic regimen, considering that iron
inhibits the replication of HCV in permissive Huh7.5.1 cells [1].
We completely agree that this hypothesis merits further
exploration. It will be interesting to examine the effects of ribavi-
rin in the infectious HCV replicon model, with or without exoge-
nous iron administration. Nevertheless, given the complexity of
the pharmacological responses to ribavirin in vivo, which
impinges on systemic iron trafﬁc, we should be cautious in
extrapolating data from this cell culture model. Moreover, the
iron deposition in hepatocytes of patients did not appear to affect
the ‘‘biochemical or histologic response to ribavirin therapy’’ over
a period of 9 months, even though sustained virological response
(SVR) was not assessed [2]. A more recent prospective study eval-
uated how iron perturbations affect combination therapy with
pegylated interferon and ribavirin [4]. The data revealed a nega-
tive correlation between iron load in Kupffer cells and the pros-
pect of achieving SVR, and did not provide any evidence for
potential beneﬁts of hepatocyte iron accumulation. Further clin-
ical studies with HCV-infected patients and, possibly, also exper-
iments with humanized mouse models for HCV infection [5], may
provide a more clear view on how hepatocyte iron accumulation
interferes with antiviral therapy.
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